瑞典全国研究:COVID-19疫苗接种后成人心血管事件风险
该研究基于瑞典全国登记数据(n=8 070 674),评估接种每剂COVID-19疫苗后多个风险窗内的心肌炎/心包炎、心律失常、心力衰竭、心肌梗死及脑血管事件风险。
要点
- 完全接种可显著降低多种重症COVID-19相关心血管结局风险。
- mRNA疫苗后1–2周心肌炎/心包炎风险增加,与已知一致。
- 第一、二剂后室性早搏和短暂性脑缺血发作风险轻度升高。
核心结论
- 接种COVID-19疫苗后心肌炎/心包炎(仅mRNA疫苗)、室性早搏和短暂性脑缺血发作风险短暂增加,但完全接种大幅降低多种更严重的COVID-19相关心血管结局风险。
研究设计与样本
- 瑞典全国登记为基础的队列研究,纳入所有瑞典成人(n=8 070 674),评估每剂疫苗接种后多个风险窗内的心血管事件风险,使用Cox回归模型估计风险比(HR)及95%置信区间(CI),并与未接种者比较。
主要发现
- mRNA疫苗接种后1–2周心肌炎和心包炎风险增加得到重复验证。
- 第一剂后室性早搏HR 1.17(95% CI 1.06–1.28),第二剂后HR 1.22(95% CI 1.10–1.36),在老年人和男性中更强。
- 短暂性脑缺血发作风险轻度增加,HR 1.13(95% CI 1.05–1.23),主要见于老年人。
临床怎么用
- 应强调完全接种COVID-19疫苗对降低重症COVID-19相关心血管结局的净获益,同时关注mRNA疫苗后年轻男性心肌炎/心包炎的罕见风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: While the rationale for coronavirus disease 2019 (COVID-19) vaccination is to reduce complications and overall mortality, some cardiovascular complications from the vaccine itself have been demonstrated. Myocarditis and pericarditis are recognized as rare acute adverse events after mRNA vaccines in young males, while evidence regarding other cardiovascular events remains limited and inconsistent. This study assessed the risks of several cardiovascular and cerebrovascular events in a Swedish nationwide register-based cohort. METHODS: Post-vaccination risk of myocarditis/pericarditis, dysrhythmias, heart failure, myocardial infarction, and cerebrovascular events (transient ischaemic attack and stroke) in several risk windows after each vaccine dose were assessed among all Swedish adults (n = 8 070 674). Hazard ratios (HRs) with 95% confidence intervals (95% CIs) compared with unvaccinated were estimated from Cox regression models adjusted for potential confounders. RESULTS: For most studied outcomes, decreased risks of cardiovascular events post-vaccination were observed, especially after dose three (HRs for dose three ranging from .69 to .81), while replicating the increased risk of myocarditis and pericarditis 1-2 weeks after COVID-19 mRNA vaccination. Slightly increased risks, similar across vaccines, were observed for extrasystoles [HR 1.17 (95% CI 1.06-1.28) for dose one and HR 1.22 (95% CI 1.10-1.36) for dose two, stronger in elderly and males] but not for arrhythmias and for transient ischaemic attack [HR 1.13 (95% CI 1.05-1.23), mainly in elderly] but not for stroke. CONCLUSIONS: Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.
引用
- Xu Y, Li H, Santosa A, et al. Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study. Eur Heart J. 2025. PMID: 39344920. doi:10.1093/eurheartj/ehae639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。